Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations.

Covy JP, Yuan W, Waxman EA, Hurtig HI, Van Deerlin VM, Giasson BI.

Mov Disord. 2009 Jan 15;24(1):32-9. doi: 10.1002/mds.22096.

2.

α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.

Covy JP, Giasson BI.

Neurotoxicology. 2011 Oct;32(5):622-9. doi: 10.1016/j.neuro.2011.01.003. Epub 2011 Jan 14. Review.

3.

[Advance of the study on LRRK2 gene in Parkinson's disease].

Zhang Y, Chen S.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Dec;25(6):657-9. Review. Chinese.

PMID:
19065525
4.

Clinical genetics of Parkinson's disease and related disorders.

Wider C, Wszolek ZK.

Parkinsonism Relat Disord. 2007;13 Suppl 3:S229-32. doi: 10.1016/S1353-8020(08)70007-5. Review.

PMID:
18267241
5.

[Clinical molecular genetics for PARK8 (LRRK2)].

Tomiyama H, Hatano T, Hattori N.

Brain Nerve. 2007 Aug;59(8):839-50. Review. Japanese.

PMID:
17713120
7.

Co-occurrence of sporadic parkinsonism and late-onset Alzheimer's disease in a Brazilian male with the LRRK2 p.G2019S mutation.

Santos-Rebouças CB, Abdalla CB, Baldi FJ, Martins PA, Corrêa JC, Gonçalves AP, Cunha MS, Borges MB, Pereira JS, Laks J, Pimentel MM.

Genet Test. 2008 Dec;12(4):471-3. doi: 10.1089/gte.2008.0042. Review.

PMID:
19072560
8.

Mutations in LRRK2 as a cause of Parkinson's disease.

Giasson BI, Van Deerlin VM.

Neurosignals. 2008;16(1):99-105. Epub 2007 Dec 5. Review.

PMID:
18097165
9.

TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.

Ling H, Kara E, Bandopadhyay R, Hardy J, Holton J, Xiromerisiou G, Lees A, Houlden H, Revesz T.

Neurobiol Aging. 2013 Dec;34(12):2889.e5-9. doi: 10.1016/j.neurobiolaging.2013.04.011. Epub 2013 May 9. Review.

10.

Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.

Devine MJ, Lewis PA.

FEBS J. 2008 Dec;275(23):5748-57. doi: 10.1111/j.1742-4658.2008.06707.x. Review.

11.

Autosomal dominant Parkinson's disease and the route to new therapies.

Morris HR.

Expert Rev Neurother. 2007 Jun;7(6):649-56. Review.

PMID:
17563248
12.

LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?

Taylor JP, Mata IF, Farrer MJ.

Trends Mol Med. 2006 Feb;12(2):76-82. Epub 2006 Jan 10. Review.

PMID:
16406842
13.

Clinical and pathologic features of families with LRRK2-associated Parkinson's disease.

Whaley NR, Uitti RJ, Dickson DW, Farrer MJ, Wszolek ZK.

J Neural Transm Suppl. 2006;(70):221-9. Review.

PMID:
17017533
14.

Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.

Lu YW, Tan EK.

J Neurosci Res. 2008 Jul;86(9):1895-901. doi: 10.1002/jnr.21656. Review.

PMID:
18338801
15.

The role of the LRRK2 gene in Parkinsonism.

Li JQ, Tan L, Yu JT.

Mol Neurodegener. 2014 Nov 12;9:47. doi: 10.1186/1750-1326-9-47. Review.

16.

Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease.

Braithwaite SP, Voronkov M, Stock JB, Mouradian MM.

Neurochem Int. 2012 Nov;61(6):899-906. doi: 10.1016/j.neuint.2012.01.031. Epub 2012 Feb 8. Review.

PMID:
22342821
17.

What causes cell death in Parkinson's disease?

Gupta A, Dawson VL, Dawson TM.

Ann Neurol. 2008 Dec;64 Suppl 2:S3-15. doi: 10.1002/ana.21573. Review.

18.

Genetics of parkinsonism.

Lewthwaite AJ, Nicholl DJ.

Curr Neurol Neurosci Rep. 2005 Sep;5(5):397-404. Review.

PMID:
16131423
19.

Genetic mouse models of Parkinson's disease The state of the art.

Magen I, Chesselet MF.

Prog Brain Res. 2010;184:53-87. doi: 10.1016/S0079-6123(10)84004-X. Review.

PMID:
20887870

Supplemental Content

Support Center